RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Second Xiangya Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Second Xiangya Hospital中南大学湘雅二医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07820423, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. 1. Patients with non-small cell lung cancer (NSCLC) confirmed by biopsy or postoperative pathological examination.

    Inclusion criterion 1

    Patients with available clinical and pathological data required for analysis.

    Inclusion criterion 4

  3. Patients with complete preoperative chest CT imaging data. 4. Patients whose preoperative chest CT showed a well-defined air-containing cystic component within the tumor, consistent with the radiological features of lung cancer associated with cystic airspaces (LCCA).

    Inclusion criterion 3

    Patients with other primary malignancies. 4. Patients with missing preoperative chest CT images or CT images of insufficient quality for analysis.

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07820423, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1. Patients with non-small cell lung cancer (NSCLC) confirmed by biopsy or postoperative pathological examination.
  • Patients who underwent surgical resection of a pulmonary tumor, including lobectomy, segmentectomy, or wedge resection.
  • Patients with complete preoperative chest CT imaging data. 4. Patients whose preoperative chest CT showed a well-defined air-containing cystic component within the tumor, consistent with the radiological features of lung cancer associated with cystic airspaces (LCCA).
  • Patients with available clinical and pathological data required for analysis.

Exclusion Criteria:

  • 1. Patients with a history of pulmonary diseases that may cause cystic lung lesions, such as pulmonary tuberculosis, pulmonary fungal infection, lymphangioleiomyomatosis (LAM), or Birt-Hogg-Dubé (BHD) syndrome. Emphysema will not be considered an exclusion criterion; however, patients with severe emphysema will be excluded if it significantly affects the identification, boundary delineation, or imaging feature assessment of the target lesion.
  • Patients who received systemic antitumor therapy before enrollment, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
  • Patients with other primary malignancies. 4. Patients with missing preoperative chest CT images or CT images of insufficient quality for analysis.
  • Patients without a definite pathological diagnosis or with incomplete pathological results.
  • Patients with missing clinical data.

Quoted from ClinicalTrials.gov, NCT07820423, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07820423, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07820423